STRT Invest Invests in Discovery Evolution

to Advance the Next Generation of Digital Biologic Discovery

July 1st 2026

Vienna, Austria / Budapest, Hungary — Discovery Evolution, the Vienna-based biotechnology company developing a digital-first platform for the discovery of biologics, today announced a strategic investment from STRT Invest, one of Central and Eastern Europe’s leading early-stage technology investors. Financial terms of the investment were not disclosed.

The investment will support the continued advancement of Discovery Evolution’s proprietary RedQueen platform and the initiation of the company’s internal therapeutic discovery pipeline. By combining digital evolution, computational biophysics, and artificial intelligence, RedQueen enables the discovery of therapeutic antibodies against some of the most challenging drug targets, including G protein-coupled receptors (GPCRs).

The partnership reflects a shared ambition to build globally competitive deep-tech companies originating from Central and Eastern Europe.

“Discovery Evolution represents exactly the kind of deep-tech innovation with global potential that STRT Invest specifically seeks in the Central and Eastern European region. By combining AI and digital modeling, the team is transforming a traditionally slow and expensive process, where time and cost savings can ultimately be measured in human lives. We are convinced that the RedQueen platform brings a new dynamic to complex drug discovery, and we are backing their international expansion with capital, an extensive network, and strategic support.” said Peter Langmar, Investment Director of STRT Invest.

Drug discovery remains a lengthy and expensive process, particularly for complex membrane proteins such as GPCRs, which account for approximately one-third of all approved drug targets yet remain difficult to address using conventional antibody discovery technologies. Discovery Evolution tackles this challenge by shifting much of the discovery process from the laboratory into a computational environment, dramatically accelerating candidate generation while reducing experimental costs.

“We are delighted to welcome STRT Invest as a strategic partner,” said Harold P. de Vladár, Founder and CEO of Discovery Evolution. “Beyond capital, STRT brings entrepreneurial experience, an exceptional network, and a long-term commitment to helping technology companies scale internationally. This investment strengthens our ability to further develop RedQueen, expand our discovery pipeline, and accelerate collaborations with pharmaceutical partners.”

Since its founding, Discovery Evolution has successfully generated and experimentally validated antibodies discovered through its RedQueen platform and continues to expand its capabilities in the discovery of therapeutics against GPCRs and other challenging membrane proteins. In parallel, the company has secured competitive non-dilutive funding from the Austrian Research Promotion Agency (FFG) and aws (Austria Wirtschaftsservice), providing further validation of its technology and supporting the continued development of its RedQueen platform and next-generation state-specific antibody discovery capabilities.

Discovery Evolution Appoints Scientific Advisory Board to Advance Digital-First Biologics Discovery

June 1st 2026

Discovery Evolution is pleased to announce the appointment of three distinguished experts to its Scientific Advisory Board: Dr. Catherine Hutchings, Dr. Bryn Williams-Jones, and Professor Krista Rombouts. The formation of the Scientific Advisory Board marks an important milestone as Discovery Evolution continues to expand its proprietary platform for the digital discovery and evolution of novel biologics targeting complex and historically difficult- to-drug diseases.

The newly appointed advisors bring extensive expertise spanning antibody discovery, translational medicine, computational drug discovery, regenerative biology, and therapeutic innovation. Their collective experience will help guide Discovery Evolution’s mission to transform biologics discovery through the integration of computational biology, in silico directed evolution, and biologics engineering.

Dr. Catherine Hutchings is a recognized leader in antibody drug discovery with more than two decades of experience developing biologics against challenging therapeutic targets and advancing next-generation discovery platforms.

Dr. Bryn Williams-Jones brings extensive experience in drug discovery, bioinformatics, and computational approaches to therapeutic development. His expertise in translating digital technologies into pharmaceutical innovation will support the continued advancement of Discovery Evolution’s platform.

Professor Krista Rombouts, Professor of Experimental Liver and Digestive Sciences at University College London (UCL), is internationally recognized for her work in fibrosis, regenerative medicine, tumour microenvironment biology, and translational disease research.

“We are delighted to welcome Catherine, Bryn, and Krista to our Scientific Advisory Board,” said Harold Vladar, Founder and CEO of Discovery Evolution. “Their scientific leadership and diverse expertise will be invaluable as we continue advancing our digital-first platform for biologics discovery. Together, we aim to unlock new therapeutic opportunities against targets that have traditionally been beyond the reach of conventional discovery approaches.”

The Scientific Advisory Board will provide strategic guidance on platform development, therapeutic applications, translational opportunities, and long-term scientific direction as Discovery Evolution continues to scale its biologics discovery capabilities.We look forward to working closely with our advisors as we continue building the future of biologics discovery.

February 2, 2026

Discovery Evolution is proud to announce the successful identification of multiple antibody hits against two high-value GPCR targets using its proprietary RedQueen™ platform. By combining structure-based modeling, evolutionary computation, and advanced AI-driven prediction, RedQueen digitally explores antibody sequence space to design optimized binders for challenging membrane protein targets.

The resulting antibodies were synthesized and experimentally validated by Bio-Layer Interferometry (BLI), demonstrating nanomolar binding affinities against native target receptors. GPCRs remain among the most important yet technically challenging target classes in drug discovery, making these results an important validation of Discovery Evolution’s digital discovery capabilities.

These candidates represent the first asset set generated through the platform and will now advance into functional characterization studies to evaluate their pharmacological activity.

This discovery program was supported through an FFG-funded initiative focused on the development and advancement of the RedQueen platform.

September 15, 2025

Discovery Evolution today announced the successful completion of the first large-scale deployment of its proprietary RedQueen™ digital discovery platform in a campaign code-named “LoadRunner.” The campaign covered nearly 30 protein targets, including a broad range of clinically relevant GPCRs, representing a major milestone in the validation and scalability of the platform.

RedQueen™ is a next-generation digital antibody discovery platform specifically engineered for challenging membrane protein targets such as GPCRs. By combining structure-based modeling, AI-guided prediction, and evolutionary computation, the platform performs directed digital evolution to design antibody binders optimized not only for target affinity, but also for key discovery, developability, and manufacturability parameters.

During the LoadRunner campaign, RedQueen™ explored more than 100,000 antibody candidates across multiple target classes, efficiently generating prioritized antibody sequences and structural models predicted to exhibit high-affinity binding characteristics. The campaign demonstrated both the computational scalability and precision of the platform, establishing the foundation for subsequent experimental validation programs.

The development of the RedQueen™ platform was supported through an FFG-funded initiative together with the AWS SeedFinancing program.